| Hint | Answer | % Correct |
|---|---|---|
| $63.6B | Pfizer | 90%
|
| $88.8B | Johnson & Johnson | 88%
|
| $54.1B | AstraZeneca | 63%
|
| $65.3B | Roche | 59%
|
| $64.2B | Merck | 54%
|
| $26B | Bayer | 51%
|
| $50.3B | Novartis | 49%
|
| $42.1B | Novo Nordisk | 49%
|
| $45B | Eli Lilly | 46%
|
| $44.46B | Sanofi | 44%
|
| $40.1B | GSK | 41%
|
| $3.24B | Moderna | 41%
|
| $56.3B | Abbvie | 37%
|
| $33.4B | Amgen | 29%
|
| $16.5B | Teva | 22%
|
| $28.6B | Gilead | 20%
|
| $9.68B | Biogen | 17%
|
| $10.4B | Sandoz | 17%
|
| $48.3B | BMS | 15%
|
| $14.2B | Regeneron | 15%
|
| $29B | Boehringer Ingelheim | 10%
|
| $30.9B | Takeda | 10%
|
| $2.8B | Apotex | 7%
|
| $10.64B | Baxter | 7%
|
| $2.98B | BioNTech | 7%
|
| $15.2B | CSL | 7%
|
| $10.6B | Daiichi Sankyo | 7%
|
| $4.04B | STADA | 7%
|
| $11.02B | Vertex | 7%
|
| $5.21B | Menarini | 5%
|
| $14.7 | Viatris | 5%
|
| $2.33B | Angelini | 2%
|
| $2.3B | Argenx | 2%
|
| $10.6B | Astellas | 2%
|
| $3.85B | Chiesi | 2%
|
| $1.92B | Eurofarma | 2%
|
| $8B | Fresenius Kabi | 2%
|
| $8.16B | Grifols | 2%
|
| $4.24B | Incyte | 2%
|
| $19.1B | Merck KGaA | 2%
|
| $9.19B | Otsuka | 2%
|
| $3.5B | Pierre Fabre | 2%
|
| $2.87B | Shionogi | 2%
|
| $6.66B | UCB | 2%
|
| $2.12B | Alfasigma | 0%
|
| $9.63B | Bausch Health | 0%
|
| $4.52B | Biomerieux | 0%
|
| $2.5B | Celltrion | 0%
|
| $7.74B | Chugai | 0%
|
| $4.9B | Eisai | 0%
|
| $2.64B | Ferring | 0%
|
| $3.26B | Genmab | 0%
|
| $1.8B | Grunenthal | 0%
|
| $1.31B | Hypera | 0%
|
| $3.68B | Ipsen | 0%
|
| $4.07B | Jazz | 0%
|
| $2.92B | Kyowa Kirin | 0%
|
| $1.89B | LEO | 0%
|
| $3.19B | Lundbeck | 0%
|
| $6.4B | Organon | 0%
|
| $4.37B | Perrigo | 0%
|
| $6.39B | Servier | 0%
|
| $2.08B | Sumitomo pharma | 0%
|